In a 51-year-old woman with elevated hemoglobin, elevated hematocrit, and borderline macrocytic mean corpuscular volume who is using estradiol patches and progesterone, what is the most likely diagnosis and appropriate treatment?

Diagnosis: Polycythemia Vera

This 51-year-old woman most likely has polycythemia vera (PV), and her estradiol patches should be discontinued immediately given the significantly elevated thrombotic risk from combining erythrocytosis with exogenous estrogen. 1

Diagnostic Reasoning

The patient's hemoglobin of 16.6 g/dL and hematocrit of 50.6% are markedly elevated for a woman, exceeding the 95th percentile for sex-adjusted normal values. 1 In women, PV should be suspected when hemoglobin/hematocrit exceeds sex-adjusted norms, and a hematocrit >45% in women is particularly concerning. 1

Key Diagnostic Steps

• Measure serum erythropoietin (EPO) level immediately. 1 In PV, serum EPO is typically low (sensitivity ~70%, specificity >90%). 1 A low or normal EPO level warrants further investigation, while an elevated EPO argues against PV. 1

• Obtain bone marrow examination with cytogenetics if EPO is low or normal. 1 Bone marrow histology in PV characteristically shows hypercellularity, increased megakaryocytes with clustering, giant megakaryocytes, pleomorphism, and decreased iron stores. 1

• The borderline macrocytic MCV of 99 fL is consistent with PV and does not exclude the diagnosis, as MCV can be normal or slightly elevated in PV, particularly when iron deficiency (common in PV from phlebotomy or occult bleeding) is absent. 2

Critical Hormone Consideration

Exogenous estradiol can independently elevate hematocrit and hemoglobin levels. 3 High total and free estradiol levels are associated with elevated hematocrit (OR 2.84 for high vs normal hematocrit with increasing estradiol). 3 However, the degree of elevation in this patient (hematocrit 50.6%) exceeds what would be expected from hormone therapy alone and strongly suggests underlying PV.

Immediate Treatment

1. Discontinue Estradiol Patches Immediately

The combination of elevated hematocrit and oral/transdermal estrogen creates extreme thrombotic risk. 4, 5 While transdermal estrogen alone has lower VTE risk than oral estrogen (OR 0.9 vs 4.2), 5 any estrogen therapy in the setting of polycythemia dramatically amplifies thrombosis risk. 1, 4

• Estrogen plus progestin therapy increases stroke risk (33 vs 25 per 10,000 women-years), coronary events, and venous thromboembolism (35 vs 17 per 10,000 women-years). 4
• The patient's progesterone formulation matters: norpregnane derivatives increase VTE risk 4-fold (OR 3.9), while micronized progesterone appears safer (OR 0.7). 5

2. Initiate Phlebotomy Urgently

Target hematocrit <45% through therapeutic phlebotomy. 1 The CYTO-PV trial definitively showed that maintaining hematocrit strictly below 45% efficiently reduces thrombotic events. 1

• For women, target an even lower hematocrit of 42% due to physiological sex differences. 1
• Phlebotomy serves as both emergency therapy for very high hematocrit with hyperviscosity symptoms and long-term maintenance. 1
• Perform phlebotomy with careful fluid replacement to avoid hypotension, especially given cardiovascular risk from estrogen therapy. 1

3. Start Low-Dose Aspirin

Initiate aspirin 81 mg daily unless contraindicated. 1 The ECLAP study demonstrated that low-dose aspirin significantly reduces cardiovascular death, myocardial infarction, stroke, and major venous thromboembolism in PV. 1

• Caution: If platelet count exceeds 1000 × 10⁹/L, aspirin may paradoxically increase bleeding risk and should be used cautiously. 1

4. Risk Stratification for Cytoreductive Therapy

At age 51, assess for additional high-risk features. 1 Cytoreductive therapy with hydroxyurea or interferon-alpha is indicated for high-risk PV patients (age >60 years OR history of vascular event). 1

• This patient does not meet age criteria but should be evaluated for prior thrombotic events given her estrogen use.
• If she has had any thrombotic event, she qualifies as high-risk and requires cytoreductive therapy. 1
• Hydroxyurea is first-line cytoreductive therapy (Level II, A evidence), though interferon-alpha may be preferred in younger patients due to uncertain long-term leukemogenic risk of hydroxyurea. 1

Critical Pitfalls to Avoid

• Do not attribute the elevated hematocrit solely to hormone therapy without excluding PV, as this delay increases thrombotic risk substantially. 1
• Do not continue estrogen therapy while investigating erythrocytosis, as the combined thrombotic risk is prohibitive. 4, 5
• Do not target hematocrit <45% in women without considering the lower target of 42% recommended for sex-specific physiology. 1
• Aggressively manage all vascular risk factors including smoking cessation, as these compound thrombotic risk in PV. 1